Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonia Burrel

Showing results (101-110 of 109) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 109 results.
Nature Communications|December 8, 2022
Author Correction: Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19Nicolas de Prost, Etienne Audureau, Nicholas Heming, et al.
Annals of Intensive Care|June 14, 2024
Correction: COVID-19 associated pulmonary aspergillosis in critically-ill patients: a prospective multicenter study in the era of Delta and Omicron variantsPierre Bay, Etienne Audureau, Sébastien Préau, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|March 30, 2021
Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patientsChristelle Vauloup-Fellous, Sarah Maylin, Claire Périllaud-Dubois, et al.
Annals of Intensive Care|April 24, 2024
COVID-19 associated pulmonary aspergillosis in critically-ill patients: a prospective multicenter study in the era of Delta and Omicron variantsPierre Bay, Etienne Audureau, Sébastien Préau, et al.
The Lancet. Microbe|June 2, 2026
Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in FranceSlim Fourati, Alawiya Reslan, Jérôme Bourret, et al.
Science Immunology|July 20, 2022
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNsPaul Bastard, Sara E Vazquez, Jamin Liu, et al.
Research Square|January 19, 2022
The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodiesJeremy Manry, Paul Bastard, Adrian Gervais, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2022
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodiesJérémy Manry, Paul Bastard, Adrian Gervais, et al.
Science Immunology|August 20, 2021
Autoantibodies neutralizing type I IFNs are present in <b>~</b>4% of uninfected individuals over 70 years old and account for <b>~</b>20% of COVID-19 deathsPaul Bastard, Adrian Gervais, Tom Le Voyer, et al.
Pageof 11

Showing results (101-110 of 109) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 109 results.
Nature Communications|December 8, 2022
Author Correction: Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19Nicolas de Prost, Etienne Audureau, Nicholas Heming, et al.
Annals of Intensive Care|June 14, 2024
Correction: COVID-19 associated pulmonary aspergillosis in critically-ill patients: a prospective multicenter study in the era of Delta and Omicron variantsPierre Bay, Etienne Audureau, Sébastien Préau, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|March 30, 2021
Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patientsChristelle Vauloup-Fellous, Sarah Maylin, Claire Périllaud-Dubois, et al.
Annals of Intensive Care|April 24, 2024
COVID-19 associated pulmonary aspergillosis in critically-ill patients: a prospective multicenter study in the era of Delta and Omicron variantsPierre Bay, Etienne Audureau, Sébastien Préau, et al.
The Lancet. Microbe|June 2, 2026
Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in FranceSlim Fourati, Alawiya Reslan, Jérôme Bourret, et al.
Science Immunology|July 20, 2022
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNsPaul Bastard, Sara E Vazquez, Jamin Liu, et al.
Research Square|January 19, 2022
The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodiesJeremy Manry, Paul Bastard, Adrian Gervais, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2022
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodiesJérémy Manry, Paul Bastard, Adrian Gervais, et al.
Science Immunology|August 20, 2021
Autoantibodies neutralizing type I IFNs are present in <b>~</b>4% of uninfected individuals over 70 years old and account for <b>~</b>20% of COVID-19 deathsPaul Bastard, Adrian Gervais, Tom Le Voyer, et al.
Pageof 11